Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells

Biochemical Pharmacology

Volumn 88, Issue 1, 2014, Pages 119-127

  Ko, Jen Chung ^a,b,c   Chiu, Hsien Chun ^d   Syu, Jhan Jhang ^d   Jian, Yi Jun ^d   Chen, Chien Yu ^d   Jian, Yun Ting ^d   Huang, Yi Jhen ^d   Wo, Ting Yu ^d   Lin, Yun Wei ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b YUANPEI UNIVERSITY   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

AKT; ERK1 2; Erlotinib; Non small cell lung cancer; Tamoxifen; Thymidine phosphorylase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ERLOTINIB; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN KINASE B; SMALL INTERFERING RNA; TAMOXIFEN; THYMIDINE PHOSPHORYLASE; WORTMANNIN;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INACTIVATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; CANCER SURVIVAL; CYTOTOXICITY; DRUG APPROVAL; ENZYME ACTIVATION; H1975 CELL LINE; H520 CELL LINE; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER;

ACTINOMYCIN D (PUBCHEM CID: 2019); AKT; CRYSTAL VIOLET (PUBCHEM CID: 11057); CYCLOHEXIMIDE (PUBCHEM CID: 6197); ERK1/2; ERLOTINIB; ERLOTINIB (PUBCHEM CID: 176870); L-GLUTAMINE (PUBCHEM CID: 5961); LY294002 (PUBCHEM CID: 3973); NON-SMALL-CELL LUNG CANCER; PENICILLIN (PUBCHEM CID: 5904); SODIUM BICARBONATE (PUBCHEM CID: 516892); STREPTOMYCIN (PUBCHEM CID: 19649); TAMOXIFEN; TAMOXIFEN (PUBCHEM CID: 2733526); THYMIDINE PHOSPHORYLASE; TRYPAN BLUE (PUBCHEM CID: 9562061); U0126 (PUBCHEM CID: 3006531); WORTMANNIN (PUBCHEM CID: 312145);

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; TAMOXIFEN; THYMIDINE PHOSPHORYLASE; TIME FACTORS;

EID: 84896728567     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.01.010     Document Type: Article

References (49)

1. S.H. Landis, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics, 1999 CA Cancer J Clin 49 1 1999 8 31 (Pubitemid 29094959)
2. G.A. Silvestri, and S.G. Spiro Carcinoma of the bronchus 60 years later Thorax 61 2006 1023 1028 (Pubitemid 44852015)
3. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
4. C.L. Arteaga EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs J Clin Oncol 21 2003 289s 291s
5. E. Raymond, S. Faivre, and J.P. Armand Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 Suppl 1 2000 15 23 discussion 41-42
6. E. Felip, and R. Rosell Clinical experience with erlotinib in non-small-cell lung cancer Drugs Today (Barc) 42 2006 147 156
7. J. Schlessinger Ligand-induced, receptor-mediated dimerization and activation of EGF receptor Cell 110 2002 669 672 (Pubitemid 35283957)
8. T. Shibata, T. Kawano, H. Nagayasu, K. Okumura, M. Arisue, and J. Hamada et al. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth Tumour Biol 17 1996 168 175 (Pubitemid 26151481)
9. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, and S. Thongprasert et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
10. I.N. White Tamoxifen: is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans Curr Drug Metab 4 2003 223 239 (Pubitemid 36656480)
11. D.H. Phillips Understanding the genotoxicity of tamoxifen Carcinogenesis 22 2001 839 849
12. S. Basu, R. Ma, P.J. Boyle, B. Mikulla, M. Bradley, and B. Smith et al. Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis-platin, Tamoxifen, Melphalan, Betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside Glycoconj J 20 2004 563 577 (Pubitemid 41406513)
13. M.F. El Etreby, Y. Liang, and R.W. Lewis Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture Prostate 43 2000 31 42 (Pubitemid 30164241)
14. M. Tavassoli, J. Soltaninia, J. Rudnicka, D. Mashanyare, N. Johnson, and J. Gaken Tamoxifen inhibits the growth of head and neck cancer cells and sensitizes these cells to cisplatin induced-apoptosis: role of TGF-beta1 Carcinogenesis 23 2002 1569 1575
15. R. Zhou, O. Treeck, F. Horn, and O. Ortmann Effects of prolonged tamoxifen treatment on receptor expression and apoptosis of ovarian cancer cells Gynecol Oncol 96 2005 678 683 (Pubitemid 40267684)
16. A.M. Donson, M.D. Weil, and N.K. Foreman Tamoxifen radiosensitization in human glioblastoma cell lines J Neurosurg 90 1999 533 536 (Pubitemid 29104603)
17. I.V. Bijnsdorp, K. Azijli, E.E. Jansen, M.M. Wamelink, C. Jakobs, and E.A. Struys et al. Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells Biochem Pharmacol 80 2010 786 792
18. H. Hirano, K. Tanioka, S. Yokoyama, S. Akiyama, and J. Kuratsu Angiogenic effect of thymidine phosphorylase on macrophages in glioblastoma multiforme J Neurosurg 95 2001 89 95 (Pubitemid 32799777)
19. R. Andres, J.I. Mayordomo, R. Lara, R. Lastra, E. Ortega, and E. Polo et al. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes Clin Breast Cancer 6 2005 158 162 (Pubitemid 40975612)
20. R. Ikeda, T. Furukawa, R. Mitsuo, T. Noguchi, M. Kitazono, and H. Okumura et al. Thymidine phosphorylase inhibits apoptosis induced by cisplatin Biochem Biophys Res Commun 301 2003 358 363 (Pubitemid 36279246)
21. H.C. Jeung, X.F. Che, M. Haraguchi, T. Furukawa, C.L. Zheng, and T. Sumizawa et al. Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents Biochem Pharmacol 70 2005 13 21 (Pubitemid 40797866)
22. H.C. Jeung, X.F. Che, M. Haraguchi, H.Y. Zhao, T. Furukawa, and T. Gotanda et al. Protection against DNA damage-induced apoptosis by the angiogenic factor thymidine phosphorylase FEBS Lett 580 2006 1294 1302 (Pubitemid 43221991)
23. K. Mori, M. Hasegawa, M. Nishida, H. Toma, M. Fukuda, and T. Kubota et al. Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues Int J Oncol 17 2000 33 38
24. S. Mori, S. Takao, R. Ikeda, H. Noma, Y. Mataki, and X. Wang et al. Role of thymidine phosphorylase in Fas-induced apoptosis Hum Cell 14 2001 323 330
25. T. Tominaga, M. Toi, Y. Ohashi, and O. Abe Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients Clin Breast Cancer 3 2002 55 64 (Pubitemid 34546073)
26. Y. Nakayama, Y. Inoue, N. Nagashima, T. Katsuki, K. Matsumoto, and K. Kadowaki et al. Expression levels of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in patients with gastrointestinal cancer Anticancer Res 25 2005 3755 3761 (Pubitemid 41658449)
27. T.S. O'Brien, S.B. Fox, A.J. Dickinson, H. Turley, M. Westwood, and A. Moghaddam et al. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers Cancer Res 56 1996 4799 4804 (Pubitemid 26338087)
28. M. Relf, S. LeJeune, P.A. Scott, S. Fox, K. Smith, and R. Leek et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis Cancer Res 57 1997 963 969 (Pubitemid 27098025)
29. S. Shimaoka, S. Matsushita, T. Nitanda, A. Matsuda, T. Nioh, and T. Suenaga et al. The role of thymidine phosphorylase expression in the invasiveness of gastric carcinoma Cancer 88 2000 2220 2227 (Pubitemid 30247120)
30. T. Miyatani, N. Kurita, T. Utsunomiya, T. Iwata, M. Nishioka, and K. Yoshikawa et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer Cancer Lett 318 2012 199 205
31. J.C. Ko, S.C. Ciou, C.M. Cheng, L.H. Wang, J.H. Hong, and M.Y. Jheng et al. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells Carcinogenesis 29 2008 1448 1458
32. J.C. Ko, S.C. Ciou, J.Y. Jhan, C.M. Cheng, Y.J. Su, and S.M. Chuang et al. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells Mol Cancer Res 7 2009 1378 1389
33. L.V. Mauro, M. Dalurzo, M.J. Carlini, D. Smith, M. Nunez, and M. Simian et al. Estrogen receptor beta and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer Oncol Rep 24 2010 1331 1338
34. S.E. Olivo-Marston, L.E. Mechanic, S. Mollerup, E.D. Bowman, A.T. Remaley, and M.R. Forman et al. Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women Carcinogenesis 31 2010 1778 1786
35. J.K. Paulus, W. Zhou, P. Kraft, B.E. Johnson, X. Lin, and D.C. Christiani Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women Lung Cancer 71 2011 258 263
36. Y. Feng, J. Huang, Y. Ding, F. Xie, and X. Shen Tamoxifen-induced apoptosis of rat C6 glioma cells via PI3K/Akt, JNK and ERK activation Oncol Rep 24 2010 1561 1567
37. K.Y. Lee, J.W. Lee, H.J. Nam, J.H. Shim, Y. Song, and K.W. Kang PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells Mol Cells 32 2011 107 111
38. E.A. Perez, D.R. Gandara, M.J. Edelman, R. O'Donnell, I.J. Lauder, and M. DeGregorio Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies Cancer Invest 21 2003 1 6 (Pubitemid 36292501)
39. J.C. Ko, M.S. Tsai, Y.F. Chiu, S.H. Weng, Y.H. Kuo, and Y.W. Lin Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells J Pharmacol Exp Ther 338 2011 184 194
40. E. Sivridis, A. Giatromanolaki, K.C. Gatter, A.L. Harris, and M.I. Koukourakis Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma Cancer 95 2002 1055 1063 (Pubitemid 34925357)
41. G.H. Zhu, and E.L. Schwartz Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin Mol Pharmacol 64 2003 1251 1258 (Pubitemid 37310757)
42. G.H. Zhu, M. Lenzi, and E.L. Schwartz The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells Oncogene 21 2002 8477 8485 (Pubitemid 36054888)
43. K.F. Ouchi, M. Yanagisawa, F. Sekiguchi, and Y. Tanaka Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models Cancer Chemother Pharmacol 57 2006 693 702
44. P.A. Hershberger, L.P. Stabile, B. Kanterewicz, M.E. Rothstein, C.T. Gubish, and S. Land et al. Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells J Steroid Biochem Mol Biol 116 2009 102 109
45. H. Shen, Y. Yuan, J. Sun, W. Gao, and Y.Q. Shu Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects Biomed Pharmacother 64 2010 88 92
46. Q. Yang, T. Sakurai, L. Shan, G. Yoshimura, Z. Yu, and T. Suzuma et al. Thymidine phosphorylase expression correlates with tumor differentiation and Bcl-2 in invasive breast cancer Breast Cancer 7 2000 210 214
47. J.C. Pole, L.I. Gold, T. Orton, R. Huby, and P.L. Carmichael Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen Toxicology 206 2005 91 109 (Pubitemid 39601046)
48. G. Zhao, S. Zhao, T. Wang, S. Zhang, K. Lu, and L. Yu et al. Estrogen receptor beta signaling regulates the progression of Chinese non-small cell lung cancer J Steroid Biochem Mol Biol 124 2011 47 57
49. T.A. Bogush, E.A. Dudko, A.A. Beme, E.A. Bogush, A.I. Kim, and B.E. Polotsky et al. Estrogen receptors, antiestrogens, and non-small cell lung cancer Biochemistry (Mosc) 75 2010 1421 1427